Inhibition of fatty acid oxidation as an approach to treat diastolic heart failure

Heart and Metabolism

Volumn , Issue 61, 2013, Pages 20-24

  Ussher, John R ^a   Jaswal, Jagdip S ^b  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Cardiac energetics; Diastolic dysfunction; Diastolic heart failure; Fatty acid oxidation

Indexed keywords

FATTY ACID; GLUCOSE;

ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; DIASTOLIC BLOOD PRESSURE; DIASTOLIC DYSFUNCTION; DIASTOLIC HEART FAILURE; ENERGY METABOLISM; ENERGY TRANSFER; FATTY ACID OXIDATION; FATTY ACID TRANSPORT; GLUCOSE OXIDATION; GLUCOSE TRANSPORT; HEART EJECTION FRACTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART MUSCLE METABOLISM; HEART MUSCLE OXYGEN CONSUMPTION; HEART MUSCLE RELAXATION; HEART VENTRICLE COMPLIANCE; HUMAN; MORBIDITY; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC);

EID: 84891907100     PISSN: 15660338     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Hunt SA, Baker DW, Chin MH, Cinquegrani MP, Feldman AM, Francis GS et al (2001) ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the International Society for Heart and Lung Transplantation; endorsed by the Heart Failure Society of America. Circulation 104:2996-3007
2. Bhatia RS, Tu JV, Lee DS, Austin PC, Fang J, Haouzi A et al (2012) Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 355:260-269
3. Jaswal JS, Ussher JR (2012) Differentiating diastolic dysfunction from classic heart failure. Heart and Metabolism 57:4-7
4. Kenchaiah S, Evans JC, Levy D, Wilson PW, Benjamin EJ, Larson MG et al (2002) Obesity and the risk of heart failure. N Engl J Med 347:305-313
5. Velagaleti RS, Massaro J, Vasan RS, Robins SJ, Kannel WB, Levy D (2009) Relations of lipid concentrations to heart failure incidence: the Framingham Heart Study. Circulation 120:2345-2351
6. Gaasch WH, Zile MR (2011) Left ventricular structural remodeling in health and disease: with special emphasis on volume, mass, and geometry. J Am Coll Cardiol 58:1733-1740
7. Wood P, Piran S, Liu PP (2011) Diastolic heart failure: progress, treatment challenges, and prevention. Can J Cardiol 27:302-310
8. Meyer T, Shih J, Aurigemma G (2013) Heart failure with preserved ejection fraction (diastolic dysfunction). Ann Intern Med 2013;158:ITC5-1-ITC5-15; quiz ITC15-16
9. Devereux RB, Roman MJ, Palmieri V, Okin PM, Boman K, Gerdts E et al (2000) Left ventricular wall stresses and wall stress-massheart rate products in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint reduction in hypertension. J Hypertens 18:1129-1138
10. Jaswal JS, Keung W, Wang W, Ussher JR, Lopaschuk GD (2011) Targeting fatty acid and carbohydrate oxidation-a novel therapeutic intervention in the ischemic and failing heart. Biochim Biophys Acta 1813:1333-1350
11. Lopaschuk GD, Ussher JR, Folmes CD, Jaswal JS, Stanley WC (2010) Myocardial fatty acid metabolism in health and disease. Physiol Rev 90:207-258
12. Ussher JR, Lopaschuk GD (2006) Clinical implications of energetic problems in cardiovascular disease. Heart and Metabolism 32:9-17
13. Murthy MS, Pande SV (1984) Mechanism of carnitine acylcarnitine translocase-catalyzed import of acylcarnitines into mitochondria. J Biol Chem 259:9082-9089
14. Murthy MS, Pande SV (1987) Some differences in the properties of carnitine palmitoyltransferase activities of the mitochondrial outer and inner membranes. Biochem J 248:727-733
15. Murthy MS, Pande SV (1987) Malonyl-CoA binding site and the overt carnitine palmitoyltransferase activity reside on the opposite sides of the outer mitochondrial membrane. Proc Natl Acad Sci U S A 84:378-382
16. Ussher JR, Jaswal JS, Lopaschuk GD (2012) Pyridine nucleotide regulation of cardiac intermediary metabolism. Circ Res 111:628-641
17. Randle PJ, Garland PB, Hales CN, Newsholme EA (1963) The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1:785-789
18. Jaswal JS, Ussher JR, Lopaschuk GD (2009) Myocardial fatty acid utilization as a determinant of cardiac efficiency and function. Clin Lipidol 4:379-389
19. Basu R, Oudit GY, Wang X, Zhang L, Ussher JR, Lopaschuk GD, Kassiri Z (2009) Type 1 diabetic cardiomyopathy in the Akita (Ins2WT/C96Y) mouse model is characterized by lipotoxicity and diastolic dysfunction with preserved systolic function. Am J Physiol Heart Circ Physiol 297:H2096-2108
20. Zhang L, Ussher JR, Oka T, Cadete VJ, Wagg C, Lopaschuk GD (2011) Cardiac diacylglycerol accumulation in high fat-fed mice is associated with impaired insulin-stimulated glucose oxidation. Cardiovasc Res 89:148-156
21. van den Brom CE, Huisman MC, Vlasblom R, Boontje NM, Duijst S, Lubberink M et al (2009) Altered myocardial substrate metabolism is associated with myocardial dysfunction in early diabetic cardiomyopathy in rats: studies using positron emission tomography. Cardiovasc Diabetol 8:39
22. Rijzewijk LJ, van der Meer RW, Lamb HJ, de Jong HW, Lubberink M, Romijn JA et al (2009) Altered myocardial substrate metabolism and decreased diastolic function in nonischemic human diabetic cardiomyopathy: studies with cardiac positron emission tomography and magnetic resonance imaging. J Am Coll Cardiol 54:1524-1532
23. Mori J, Basu R, McLean BA, Das SK, Zhang L, Patel VB et al (2012) Agonist-induced hypertrophy and diastolic dysfunction are associated with selective reduction in glucose oxidation: a metabolic contribution to heart failure with normal ejection fraction. Circ Heart Fail 5:493-503
24. Wolkowicz PE, Urthaler F, Forrest C, Shen H, Durand J, Wei CC et al (1999) 2-Tetradecylglycidic acid, an inhibitor of carnitine palmitoyltransferase-1, induces myocardial hypertrophy via the AT1 receptor. J Mol Cell Cardiol 31:1405-1412
25. Litwin SE, Raya TE, Gay RG, Bedotto JB, Bahl JJ, Anderson PG et al (1990) Chronic inhibition of fatty acid oxidation: new model of diastolic dysfunction. Am J Physiol 258:H51-56
26. Meng D, Feng L, Chen XJ, Yang D, Zhang JN (2006) Trimetazidine improved Ca2+ handling in isoprenaline-mediated myocardial injury of rats. Exp Physiol 91:591-601
27. Li YJ, Wang PH, Chen C, Zou MH, Wang DW (2010) Improvement of mechanical heart function by trimetazidine in db/db mice. Acta Pharmacol Sin 31:560-569
28. Lovelock JD, Monasky MM, Jeong EM, Lardin HA, Liu H, Patel BG et al (2012) Ranolazine improves cardiac diastolic dysfunction through modulation of myofilament calcium sensitivity. Circ Res 110:841-850
29. Hayashida W, van Eyll C, Rousseau MF, Pouleur H (1994) Effects of ranolazine on left ventricular regional diastolic function in patients with ischemic heart disease. Cardiovasc Drugs Ther 8:741-747
30. Peterson LR, Saeed IM, McGill JB, Herrero P, Schechtman KB, Gunawardena R et al (2012) Sex and type 2 diabetes: obesityindependent effects on left ventricular substrate metabolism and relaxation in humans. Obesity (Silver Spring) 20:802-810
31. Abozguia K, Elliott P, McKenna W, Phan TT, Nallur-Shivu G, Ahmed I et al (2010) Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy. Circulation 122:1562-1569